Pharmacological management of binge eating disorder: current and emerging treatment options
Year: 2012
Type: article
Abstract: Growing evidence suggests that pharmacotherapy may be beneficial for some patients with binge eating disorder (BED), an eating disorder characterized by repetitive episodes of uncontrollable consumption of abnormally large amounts of food without inappropriate weight loss behaviors. In this paper, we provide a brief overview of BED and review the rationales and data supporting the effectiveness of specific medications or medication classes in treating patients with BED. We conclude by summarizing these data, discussing the role of pharmacotherapy in the BED treatment armamentarium, and suggesting future areas for research.
DOI: 10.2147/tcrm.s25574
Institutions: Lindner Center of HOPE, University of Cincinnati
Language: English
Subfield: Clinical Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: gold
Estimated APC paid: $2,836
Funders: Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, University of Cincinnati, Jazz Pharmaceuticals, Orexigen Therapeutics, J. Willard and Alice S. Marriott Foundation, Agency for Healthcare Research and Quality, National Institute of Mental Health
OpenAlex ID: W2027342753